Literature DB >> 9605813

Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension.

G Rolla, P Colagrande, L Brussino, C Bucca, M T Bertero, F Caligaris-Cappio.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605813     DOI: 10.1016/S0140-6736(05)78874-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Pulmonary hypertension: its assessment and treatment.

Authors:  S Brij; A J Peacock
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Effect of pulmonary rehabilitation on exhaled nitric oxide in patients with chronic obstructive pulmonary disease.

Authors:  E Clini; L Bianchi; K Foglio; R Porta; M Vitacca; N Ambrosino
Journal:  Thorax       Date:  2001-07       Impact factor: 9.139

Review 3.  Novel therapeutic strategies in scleroderma.

Authors:  C P Denton; C M Black
Journal:  Curr Rheumatol Rep       Date:  1999-10       Impact factor: 4.592

4.  Measurement of IL-13-induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells.

Authors:  Vinod Suresh; Justin D Mih; Steven C George
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-08       Impact factor: 6.914

5.  Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease.

Authors:  Natalie K Kozij; John T Granton; Philip E Silkoff; John Thenganatt; Shobha Chakravorty; Sindhu R Johnson
Journal:  Can Respir J       Date:  2017-02-14       Impact factor: 2.409

6.  Identification of biomarkers, pathways and potential therapeutic agents for salt-sensitive hypertension using RNA-seq.

Authors:  Xiaoying Chao; Zhiyuan Jiang; Guoqiang Zhong; Rongjie Huang
Journal:  Front Cardiovasc Med       Date:  2022-08-10

7.  Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy.

Authors:  Adriano R Tonelli; Sarah Haserodt; Metin Aytekin; Raed A Dweik
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.